Figure 2
From: Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
Anti-CTLA4 nanobodies binding to the MYPPPY epitope of canine CTLA4. (A) The FASTA sequence of canine CTLA4, where the conserved modeled domain has been highlighted in black and the rest in light gray. (B) A globally docked complex of anti-CTLA4 nanobody cNb6 (black) and canine CTLA4 (dim gray) with the MYPPPY epitope (dark gray) interacting with the nanobody CDRs. (C) A detailed view of the interacting molecules in (B) with intermolecular hydrogen bonds (fine gray straight lines) between Ser-Pro/Ser-Tyr/Tyr-Pro residues near the center of the image. Additionally, there are several intermolecular aromatic residue interactions around the target epitope, which represents hydrophobic interactions.
